The association between carotid or femoral atherosclerosis and low bone mass in postmenopausal women referred for osteoporosis screening. Does osteoprotegerin play a role?

Maturitas

Volumn 67, Issue 4, 2010, Pages 358-362

  Pennisi, P ^a   Russo, E ^b   Gaudio, A ^a   Veca, R ^c   D'Amico, F ^b   Mangiafico, R A ^a   Laspina, M ^a   Tringali, G ^c   Signorelli, S S ^a   Fiore, C E ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Hospital Barone Romeo Patti   (Italy)

^c Istituto Ricerca Medica Ambientale (IRMA)   (Italy)

Author keywords

Carotid plaque; Femoral plaque; Low bone mass; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; BONE DENSITY; BONE MASS; CAROTID ARTERIOGRAPHY; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME IMMUNOASSAY; FEMALE; FEMORAL ATHEROSCLEROSIS; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE;

AGED; AGED, 80 AND OVER; ARTERIES; ATHEROSCLEROSIS; BONE DENSITY; CAROTID ARTERIES; FEMALE; FEMORAL ARTERY; FEMUR; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; PLAQUE, ATHEROSCLEROTIC;

ANIMALIA;

EID: 78649497236     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.07.013     Document Type: Article

References (35)

1. A.E. Hak, H.A. Pols, A.M. van Hemert, A. Hofman, and J.C. Witteman Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study Arterioscler Thromb Vasc Biol 20 2000 1926 1931
2. D.P. Kiel, L.I. Kauppila, L.A. Cupples, M.T. Hannan, C.J. O'Donnell, and P.W. Wilson Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study Calcif Tissue Int 68 2001 271 276
3. L.B. Tanko, Y.Z. Bagger, and C. Christiansen Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women Calcif Tissue Int 73 2003 15 20
4. P. Anagnostis, A. Karagiannis, A.I. Kakafika, K. Tziomalos, V.G. Athyros, and D.P. Mikhailidis Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20 2009 197 207
5. D.L. Lacey, E. Timms, and H.L. Tan Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
6. H. Hsu, D.L. Lacey, and C.R. Dunstan Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci USA 96 1999 3540 3545
7. P. Collin-Osdoby, L. Rothe, F. Anderson, M. Nelson, W. Maloney, and P. Osdoby Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis J Biol Chem 276 2001 20659 20672
8. A. Van Campenhout, and J. Golledge Osteoprotegerin vascular calcification and atherosclerosis Atherosclerosis 204 2009 321 329
9. N. Bucay, I. Sarosi, and C.R. Dunstan Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1998 1260 1268
10. S. Kiechl, G. Schett, and G. Wenning Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease Circulation 109 2004 2175 2180
11. T. Omland, T. Ueland, and A.M. Jansson Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes J Am Coll Cardiol 51 2008 627 633
12. R.A. Mangiafico, C. Alagona, and P. Pennisi Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women Osteoporos Int 19 2008 49 56
13. M.L. Frost, R. Grella, and S.C. Millasseau Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening Calcif Tissue Int 83 2008 112 120
14. Z. Ali, A.A. Ellington, T.H. Mosley Jr., and I.J. Kullo Association of serum osteoprotegerin with ankle-brachial index and urine albumin:creatinine ratio in African-Americans and non-Hispanic whites Atherosclerosis 206 2009 575 580
15. M. Schoppet, J.R. Schaefer, and L.C. Hofbauer Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men Circulation 107 2003 e76
16. P. Ireland, D. Jolley, and G.A. Giles Food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort Asia Pac J Clin Nutr 3 1994 19 31
17. WHO Study group. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. WHO Tech Dep Ser n° 843; 1999.
18. H.P. Sennels, S. Jacobsen, and T. Jensen Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein Scand L Clin Lab Invest 67 2007 821 835
19. G. Schett, S. Kiechl, and K. Redlich Soluble RANKL and risk of nontraumatic fracture JAMA 291 2004 1108 1113 (Pubitemid 38541688)
20. P.B. Gogo, D.J. Schneider, E.F. Terrien, E. Burton, B.E. Sobel, and H.L. Dauerman Osteoprotegerin is not associated with angiographic coronary calcification J Thromb Thrombolysis 22 2006 177 183
21. M. Nybo, S.P. Johnsen, and C. Dethlefsen Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population Clin Chem 54 2008 1969 1974
22. H. Min, S. Morony, and I. Sarosi Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis J Exp Med 192 2000 463 474
23. A. Vik, E.B. Mathiesen, A.T. Notø, B. Sveinbjørnsson, J. Brox, and J.B. Hansen Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans Atherosclerosis 191 2007 128 134
24. J. Golledge, M. McCann, S. Mangan, A. Lam, and M. Karan Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis Stroke 35 2004 1636 1641
25. W.J. Sandberg, A. Yndestad, and E. Øie Enhanced T cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization Arterioscl Thromb Vasc Biol 26 2006 857 863
26. A. Crisafulli, A. Micari, and D. Altavilla Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction Clin Sci (Lond) 109 2005 389 395
27. A. Van Campenhout, and J. Golledge Osteoprotegerin, vascular calcification and atherosclerosis Atherosclerosis 204 2009 321 329
28. R. Ross Atherosclerosis: an inflammatory disease N Engl J Med 340 2004 115 126
29. A.M. Sattler, M. Schoppet, J.R. Schaefer, and L.C. Hofbauer Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease Calcif Tissue Int 74 2004 103 106
30. P. Collin-Osdoby Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin Circ Res 95 2004 1046 1057
31. M. Schoppet, K.T. Preissner, and L.C. Hofbauer RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function Arterioscl Thromb Vasc Biol 22 2002 549 553
32. Y. Asanuma, C.P. Chung, and A. Oeser Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis Atherosclerosis 195 2007 e135 e141
33. W. Zhou, and H.C. Chai Carotid and femoral plaques are distinct entities J Am Coll Surg 209 2009 S139
34. M. Cesari, B.W. Penninx, and A.B. Newman Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study Circulation 108 2003 2317 2322
35. M. Shargorodsky, M. Boaz, A. Luckish, Z. Matas, D. Gavish, and M. Mashavi Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women Atherosclerosis 204 2009 608 611